Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

Mohammed A.Al-Karkhi* MBChB, MSc, PhD
Muhammed M. Al-Ani* MBChB, MSc, FICMS
Nizar A. Jassin** MBChB, MSc, FICMS
Batool M. Mahdi*** MBChB, MSc, FICMS
Layth Abd-alailah**** MBChB, FICMS

Abstract

Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy. Treatment with infliximab gives great improvement to a large numbers of patients with RA, however, in some patients after prolonged treatment infliximab can induce anti-infliximab antibodies formation and result to loss of infliximab efficacy and active persistent disease.

Objective: to investigate the frequency of anti-infliximab antibodies in Iraqi patients with rheumatoid arthritis.

Patients and methods: fifty Iraqi RA patients (36 females and 14 males) compared with 50 control (25 healthy control and 25 case control (patients with RA on other treatment) were included in this study from begging of March 2014 till end of September 2014. All patients were diagnosed by full history, complete clinical examination and laboratory test. Anti-infliximab antibodies were measured using enzyme-linked immunosorbent assay in serum of Iraqi patients with RA treated with infliximab more than 3 months duration.

Results: Antibodies to infliximab were detected in 35 (70%) Iraqi RA patients, while the patients without detectable antibodies against infliximab were 15 (30%), also there were no anti-infliximab antibodies in the control groups.

Conclusion: In this study, nearly three quarter of the Iraqi RA patients treated with infliximab developed anti-infliximab antibodies.

Key words: rheumatoid arthritis, infliximab, anti-infliximab antibodies.

Introduction:

Rheumatoid arthritis (RA) is a common systemic autoimmune disease can affect any tissues and organs but it mainly cause a chronic synovial inflammation of joints. Although the cause of RA still unknown, genetic and environmental factors play an important role in its pathogenic mechanisms. Because the inflammatory cytokines mainly interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are elevated in synovial fluid and blood of patients with RA, so considered to be an association between these cytokines and pathogenesis of RA.

Treatment of RA with biological agents mainly infliximab showed a great improvement in daily activities of patients with RA, this agent acts as TNF-α blocker. Infliximab which is known as chimeric monoclonal antibody because it composed of constant region of human IgG1 and variable region of murine part target TNF-α, specifically binding with TNF-α result in the following outcome; neutralization of soluble TNF-α physiological effects; dissociation of TNF-α from complex with its receptor; and acts on cells produce TNF-α by the mechanisms include; antibody-dependent cell cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis of these cells. The infliximab is effective in the treatment of many autoimmune diseases such as RA, Ankylosing spondylitis, Psoriasis, Cronh’s disease and Wegener’s granulomatosis.

Although, many patients with RA had a great initial effectiveness of infliximab treatment, others not respond to this biological agents several months after treatment.

In our study we investigated the development of anti-infliximab antibodies in patients with RA who had been received this biological treatment and then recorded the relationship between the effectiveness of this agent and emergence of these antibodies.

Patients and methods:
Fifty patients (36 females and 14 males), their mean age (45.3) years who attended to medical city, Baghdad teaching hospital,
Results:
Fifty patients with RA (36 females and 14 males) their mean age was (45.24±9.15) years, and 50 control group (25 healthy and 25 case control), 32 females and 18 males, their mean age was (42.22±8.23) years were included in this study as shown in table 1.

Table 3: Distribution of anti-infliximab antibodies according to gender.

<table>
<thead>
<tr>
<th>Anti-infliximab</th>
<th>Gender</th>
<th>Number</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>+ve</td>
<td>12</td>
<td>23</td>
<td>63.9</td>
</tr>
<tr>
<td>-ve</td>
<td>2</td>
<td>13</td>
<td>36.1</td>
</tr>
<tr>
<td>Total</td>
<td>14</td>
<td>36</td>
<td>100.0</td>
</tr>
</tbody>
</table>

X² = 1.37, P = 0.242

In table 4, the anti-infliximab anti-bodies were reported in patients age groups. 10(66.7%) in patients with age (<40), 16 (76.2%) in patients in between(41-50) years, and 9(64.3%) in patients age groups (>50%). On the other hand, these anti-bodies were negative in same age groups as follow 5(33.3%) in (<40), 5(23.8%) in (41-50) and 5(35.7) in (>50) respectively, show that no statistical difference between positive and negative anti-bodies in these patients age groups.

Table 4: Distribution of anti-infliximab antibodies according to age group. Crosstab

<table>
<thead>
<tr>
<th>Anti-infliximab</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ve</td>
</tr>
<tr>
<td>&lt;=40</td>
<td>10</td>
</tr>
<tr>
<td>% within AgeGp</td>
<td>66.7%</td>
</tr>
<tr>
<td>AgeGp</td>
<td></td>
</tr>
<tr>
<td>41-50</td>
<td>16</td>
</tr>
<tr>
<td>% within AgeGp</td>
<td>76.2%</td>
</tr>
<tr>
<td>&gt;50</td>
<td>9</td>
</tr>
<tr>
<td>% within AgeGp</td>
<td>64.3%</td>
</tr>
<tr>
<td>Total</td>
<td>35</td>
</tr>
<tr>
<td>% within AgeGp</td>
<td>70.0%</td>
</tr>
</tbody>
</table>

X² = 0.68, P = 0.711

The anti-infliximab anti-bodies were detected in 35(70.0%) patients(23(65.7%) were females and 13(34.3%) were males), and not detected in 15(30.0%) patients(13(86.7%) were females and 2(13.3%) were males) with sensitivity (70%) and specificity (100%), while no antibodies were detected in control group as shown in table 2 and 3.

Table 2: Distribution of serum anti-infliximab antibodies of the case study and controls.

<table>
<thead>
<tr>
<th>Anti-infliximab Ab</th>
<th>Patients N0. %</th>
<th>Control N0. %</th>
</tr>
</thead>
<tbody>
<tr>
<td>+ve</td>
<td>35</td>
<td>50</td>
</tr>
<tr>
<td>-ve</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Student t-test = 1.72, P = 0.088
Discussion:

The rheumatoid arthritis is common autoimmune disease that more affected women than men in ratio 3:1 (17,18), the results of present study showed that nearly three quarter of the 50 Iraqi patients with RA who were treated with infliximab (3mg/kg) every 8 weeks developed antibodies to infliximab (IgG antibodies) within 3 months of treatment. Furthermore, development of these antibodies was related to decreased in response to infliximab treatment. Up to the best of our knowledge, this is the first study investigating of antibodies to infliximab in Iraqi patients with RA on infliximab infusion treatment who suffering from persistant active disease. In this study, we observed an increased in frequency of anti-infliximab anti-bodies in Iraqi patients with RA (P = 0.000001) which is highly significant and not detected in controls and majority of these antibodies were reported more in females patients than males since the disease in more common in female than male (3:1), this finding agreed with previous studies done by Gerrit and Marijin (19). There are no relation of anti-infliximab anti-bodies development with patients age group (P = 0.711). Indeed, patients with detectable anti-infliximab antibodies in their serum show lower response to treatment compared with patients without anti-infliximab anti-bodies. This indicates that formation of anti-bodies to infliximab induces the clearance of infliximab from circulation. Interestingly, we noted that in some patients who developed anti-infliximab antibodies that result in weak response to treatment, continuation of infliximab treatment with higher doses result in improvement in signs and symptoms of their diseases. This may be due to either infliximab cause induction of immune tolerance or overdosing the capacity of immune system to create these antibodies.

Conclusion:

Nearly three quarter of the Iraqi RA patients treated with infliximab developed anti-infliximab antibodies.

Author's contributions:

Study conception: Mohammed M. Al-Ani
Study design: Nizar A. Jassim
Acquisition of data analysis: Mohammed A. Al-Karkhi
Interpretation of data: Batool M. Mahdi
Critical revision: Layth ah- alaiah

References: